Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement A Randomized Clinical Trial summary

This PACULit episode reviews a phase 3, randomized, open-label multicenter trial evaluating edoxaban started within three months after surgical bioprosthetic valve replacement (aortic and/or mitral) compared with warfarin. The primary outcome was stroke or systemic embolism; edoxaban showed 0.5% vs 1.5% in warfarin with a risk difference of −1.03% (95% CI −4.34% to 1.95%), indicating comparable efficacy. Major bleeding was higher with edoxaban (4.1% vs 1.0%; risk difference 3.07%, 95% CI −0.67% to 7.27%). Intracardiac thrombus occurred only with warfarin (1.0%), while none were observed with edoxaban. Dosing adjustments were based on renal function and weight; edoxaban offers fixed dosing without routine INR monitoring and is a substrate of P-glycoprotein. Limitations include open-label design, short follow-up, and low event rates. Implications emphasize patient-specific thrombotic risk, valve position, and bleeding risk when choosing between DOACs and VKAs post-bioprosthetic valve surgery, with considerations of cost and adherence. Related analyses and ongoing data suggest DOACs may be viable alternatives, warranting individualized assessment.